LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

NCT04973527 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Both the sponsors and collaborator are considering terminating the study

Conditions

T Cell Lymphoma
T-cell Leukemia

Interventions

DRUG: Efficacy of LCAR-T2C CAR-T cells

Sponsor

Beijing Boren Hospital

Collaborators

[object Object]